This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutAboutMechanism of ActionNCCN Guidelines® Recommendations for CMLTreatment ConsiderationsEfficacyEfficacyAdult: Newly Diagnosed Patients with CP Ph+ CMLBFORE EfficacyBFORE Study DesignAdult: Ph+ CML in Patients with Resistance or Intolerance to Prior TherapyStudy 200 EfficacyStudy 200 Study DesignPediatric: CP Ph+ CML in Patients Who Are Newly Diagnosed or Resistant or Intolerant to Prior TherapyBCHILD EfficacyBCHILD Study DesignSafetySafetyAdult: Newly Diagnosed Patients with CP Ph+ CMLBFORE SafetyAdult: Ph+ CML in Patients with Resistance or Intolerance to Prior TherapyStudy 200 SafetyPediatric: CP Ph+ CML in Patients Who Are Newly Diagnosed or Resistant or Intolerant to Prior TherapyBCHILD SafetyDosingDosingAdult Dosing and AdministrationPediatric Dosing and AdministrationTherapy ManagementSupport & ResourcesSupport & ResourcesEventsMaterialsVideosCo-pay, Access, and Patient SupportDownloadable Resources
Prescribing Information Indication Patient Site
Study 200 SafetyIn a phase 1/2 trial in adults with CP, AP, or BP Ph+ CML resistant or intolerant to prior therapy

Long-term safety data

Long-term cardiac and vascular TEAEs

Tab Number 3

Tab Number 4

Tab Number 5

The safety profile of BOSULIF® (bosutinib) is well established1Warnings and precautions for BOSULIF include gastrointestinal toxicity, myelosuppression, hepatic toxicity, cardiovascular toxicity, fluid retention, renal toxicity, and embryo-fetal toxicityReferencesBased on a minimum of 105 months of follow-up.ALT=alanine aminotransferase; AR=adverse reaction; AST=aspartate aminotransferase; CML=chronic myelogenous leukemia; CP=chronic phase; SGOT=serum glutamate-oxaloacetate aminotransferase; SGPT=serum glutamate-pyruvate transaminase.DiarrheaDiarrhea (all grades) was the most common AR, occurring in 453 (83%) patients receiving BOSULIF (N=546)2
  • 90% of patients who developed diarrhea had a maximum severity of Grade 1 or 22
  • Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and fluid replacement. Withhold, dose reduce, or discontinue BOSULIF as necessary1
Patients experiencing diarrhea (n=453)2

To learn more about select adverse reactions, including therapy management suggestions and dose adjustments, click here.

Fluid retention1
  • 6% (n=30) of patients had severe (grade 3/4) fluid retention
  • 4% (n=24) of patients experienced grade 3 or 4 pleural effusion
  • 2% (n=9) of patients experienced grade 3 or 4 pericardial effusion
  • 1% (n=6) of patients experienced grade 3 edema​​​​​​​​​​​​​
How to manage fluid retention1

To manage fluid retention, monitor and manage patients using standards of care. Interrupt, dose reduce, or discontinue BOSULIF as necessary.

ReferencesBOSULIF Prescribing Information. New York, NY: Pfizer Inc.Data on file. Pfizer Inc., New York, NY.
BOSULIF® (bosutinib) has long-term cardiac and vascular safety data1

Patients with uncontrolled or significant cardiovascular disease, including prolonged QT interval, were excluded by protocol.2

Long-term follow-up of adult patients with CP Ph+ CML and with advanced leukemias
  • The long-term follow-up data analysis was based on a minimum of ~8 years (94 months) for patients with CP CML treated with 1 prior TKI (imatinib) and a minimum of 7 years (84 months) for patients with CP CML treated with imatinib and at least 1 additional TKI and for patients with advanced phase CML1
  • Total extended safety population (N=570) included patients with CP Ph+ CML (n=403) and advanced Ph+ leukemias (AP CML [n=79], BP CML [n=64], and ALL [n=24])1,2*

Example

Summary of TEAEs in adult patients receiving bosutinib for Ph+ leukemia, by TEAE cluster1Total number of patients listed at a higher level are not necessarily the sum of numbers listed below, as individual patients may report two or more different events within that category.

BOSULIF can cause cardiovascular toxicity including cardiac failure, left ventricular dysfunction, and cardiac ischemic events. Cardiac failure events occurred more frequently in previously treated adults than in those with newly diagnosed CML and were more frequent in patients with advanced age or risk factors, including previous medical history of cardiac failure. Cardiac ischemic events occurred in both previously treated adults and in those with newly diagnosed CML and were more common in adults with coronary artery disease risk factors, including history of diabetes, body mass index greater than 30, hypertension, and vascular disorders.​​​​​​2

In a single-arm study of adults with CML who were resistant or intolerant to prior therapy, cardiac failure was observed in 5.3% of patients and cardiac ischemic events were observed in 4.9% of patients treated with BOSULIF.​​​​​​2

Monitor patients for signs and symptoms consistent with cardiac failure and cardiac ischemia and treat as clinically indicated. Interrupt, dose reduce, or discontinue BOSULIF as necessary.​​​​​​2

BOSULIF is not indicated for the treatment of ALL.28-year follow-up.7-year follow-up.Cardiac includes MedDRA HLGTs cardiac arrhythmias, heart failures; PTs cardiac death, ejection fraction decreased, sudden cardiac death, sudden death; and SMQ torsades de pointes/QT prolongation (narrow).Relatedness to study treatment was determined by the investigator.Vascular includes MedDRA HLGTs coronary artery disorders, arteriosclerosis, stenosis, vascular insufficiency, and necrosis, embolism and thrombosis; HLTs in arterial therapeutic procedures (excluding aortic), vascular imaging procedures NEC, vascular therapeutic procedures NEC, central nervous system hemorrhages and cerebrovascular accidents, central nervous system vascular disorders NEC, transient cerebrovascular events, non–site-specific vascular disorders NEC, peripheral vascular disorders NEC (excluding PTs flushing and hot flush); and PTs transcatheter arterial chemoembolization, subarachnoid hemorrhage, intestinal ischemia.Hypertension includes MedDRA HLGT vascular hypertensive disorders and PTs of blood pressure abnormal, blood pressure ambulatory abnormal, blood pressure ambulatory increased, blood pressure diastolic abnormal, blood pressure diastolic increased, blood pressure increased, blood pressure systolic abnormal, blood pressure systolic increased.Effusion includes MedDRA PTs pericardial effusion, pleural effusion.
AdvP=advanced phase; ALL=acute lymphoblastic leukemia; AP=accelerated phase; ​​​​BP=blast phase; CML=chronic myelogenous leukemia; CP=chronic phase; HLGT=high-level group term; HLT=high-level term; MedDRA=Medical Dictionary for Regulatory Activities; NEC=not elsewhere classified; Ph+=Philadelphia chromosome–positive; PT=preferred term; SMQ=standardized MedDRA query; TEAE=treatment-emergent adverse event; TKI=tyrosine kinase inhibitor.
Patients with known risk factors for cardiac and vascular events tend to have the highest incidence of cardiac and vascular complications3

Close monitoring, particularly in high-risk patients, and proactive management should be standard of care before starting therapy.3

ReferencesCortes JE, Kantarjian HM, Mauro MJ, et al. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021;10(6):808-820.BOSULIF Prescribing Information. New York, NY: Pfizer Inc.Cortes JE, Khoury HJ, Kantarjian H, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016;91(6):606-616. 
Safety
Dosing and Administration

Convenient once-daily dosing

 Explore dosing options Loading
Therapy Management

Management considerations for selected adverse reactions associated with BOSULIF

 View considerations Loading
References

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-BOS-USA-0981
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
INDICATIONSBOSULIF is indicated for the treatment of:

  • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy 

  • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy
Important Safety Information Contraindications: History of hypersensitivity to BOSULIF. Reactions have included anaphylaxis. Gastrointestinal Toxicity: Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF. In the study of adults with newly diagnosed CP Ph+ CML, the median time to onset for diarrhea (all grades) was 4 days and the median duration per event was 3 days. In the study of adults with CML who were resistant or intolerant to prior therapy, median time to onset of diarrhea (all grades) was 2 days, median duration was 2 days, and the median number of episodes per patient was 3 (range 1-268). Among 49 pediatric patients with CP Ph+ CML that was newly diagnosed or resistant or intolerant to prior therapy, the median time to onset of diarrhea (all grades) was 2 days, median duration was 2 days, and the median number of episodes was 2 (range, 1–198). Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and/or fluid replacement. Withhold, dose reduce, or discontinue BOSULIF as necessary. Myelosuppression: Thrombocytopenia, anemia, and neutropenia occur with BOSULIF. Perform complete blood counts weekly for the first month and then monthly thereafter, or as clinically indicated. Withhold, dose reduce, or discontinue BOSULIF as necessary. Hepatic Toxicity: In adults with mild, moderate, or severe hepatic impairment, the recommended starting dose is 200 mg daily. BOSULIF may cause elevations in serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]). Out of 1711 adults in BOSULIF clinical trials, 2 cases consistent with drug-induced liver injury have occurred without alternative causes. In the study of adults with newly diagnosed CP Ph+ CML, the incidence of ALT and AST elevations was 68% and 56%, respectively. In adults with CML who were resistant or intolerant to prior therapy, the incidence of ALT and AST elevations was 53% and 47%, respectively; 60% of these patients experienced an increase in either ALT or AST. Among 49 pediatric patients with CP Ph+ CML that was newly diagnosed or resistant or intolerant to prior therapy, the incidence of ALT and AST elevations was 59% and 51%, respectively; 76% of patients experienced an increase in either ALT or AST.Perform hepatic enzyme tests at least monthly for the first 3 months and as clinically indicated. In patients with transaminase elevations, monitor liver enzymes more frequently. Withhold, dose reduce, or discontinue BOSULIF as necessary.  Cardiovascular Toxicity: BOSULIF can cause cardiovascular toxicity, including cardiac failure, left ventricular dysfunction, and cardiac ischemic events. Cardiac failure events occurred more frequently in previously treated adults than in those with newly diagnosed CML and were more frequent in patients with advanced age or risk factors, including previous medical history of cardiac failure. Cardiac ischemic events occurred in both previously treated adults and in those with newly diagnosed CML and were more common in adults with coronary artery disease risk factors, including history of diabetes, body mass index greater than 30, hypertension, and vascular disorders. In a randomized study of adults with newly diagnosed CML, cardiac failure occurred in 1.9% of adults treated with BOSULIF compared to 0.8% of those treated with imatinib. Cardiac ischemic events occurred in 4.9% of adults treated with BOSULIF compared to 0.8% of those treated with imatinib. In a single-arm study of adults with CML who were resistant or intolerant to prior therapy, cardiac failure was observed in 5.3% of patients and cardiac ischemic events were observed in 4.9% of patients treated with BOSULIF. Among 49 pediatric patients with CP Ph+ CML that was newly diagnosed or resistant or intolerant to prior therapy, 4 patients (8%) had Grade 1-2 cardiac events, including tachycardia (n=2), angina pectoris, right bundle branch block, and sinus tachycardia (n=1 each). Monitor patients for signs and symptoms consistent with cardiac failure and cardiac ischemia and treat as clinically indicated. Interrupt, dose reduce, or discontinue BOSULIF as necessary. Fluid Retention: Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema. Monitor and manage patients using standards of care. Interrupt, dose reduce, or discontinue BOSULIF as necessary. Renal Toxicity: An on-treatment decline in estimated glomerular filtration rate has occurred in patients treated with BOSULIF. Monitor renal function at baseline and during therapy, with particular attention to patients with preexisting renal impairment or risk factors for renal dysfunction. Lower starting doses are recommended for patients with renal impairment. For patients who have declining renal function while on BOSULIF or who cannot tolerate the starting dose, follow dose adjustment recommendations for toxicity. Embryo-Fetal Toxicity: BOSULIF can cause fetal harm. Women of childbearing potential should be advised of the potential risk to the fetus and advised to use effective contraceptive measures while on treatment and for at least 2 weeks after the final dose. Adverse Reactions: The most common adverse reactions (≥20%), in adult and pediatric patients with CML are diarrhea, abdominal pain, vomiting, nausea, rash, fatigue, hepatic dysfunction, headache, pyrexia, decreased appetite, respiratory tract infection, and constipation. The most common laboratory abnormalities (≥20%) in adult and pediatric patients are creatinine increased, hemoglobin decreased, lymphocyte count decreased, platelets decreased, ALT increased, calcium decreased, white blood cell count decreased, AST increased, absolute neutrophil count decreased, glucose increased, phosphorus decreased, urate increased, alkaline phosphatase increased, lipase increased, creatine kinase increased, and amylase increased. CYP3A Inhibitors and Inducers: Avoid concurrent use with strong or moderate CYP3A inhibitors or strong CYP3A inducers. Proton Pump Inhibitors (PPIs): Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in BOSULIF exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours. Lactation: Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment with BOSULIF and for at least 2 weeks after the last dose. Indications

BOSULIF is indicated for the treatment of:

  • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy 

  • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy
 Please see full Prescribing Information.